Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 57 for “"pemetrexed"”.
-
Active efflux transport and CNS distribution of the novel antifolate pemetrexed.
Pemetrexed (PMX, Alimta®) is a novel multi-targeted antifolate approved for the treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). Given the high incidence of brain metastasis in NSCLC patients and wide use of the classic antifolate, methotrexate (MTX), in primary …
-
Schedule-dependent interactions between pemetrexed and vinorelbine in human lung cancer cells
… was to investigate the interactions between pemetrexed and vinorelbine for human adenocarcinoma via various chemotherapy schedules. Vinorelbine and pemetrexed caused a strong dose-dependent cytotoxic effect in both HCC and cisplatin resistant HCC (HCC-res) cells. The IC50 values of …
-
Sorafenib enhances pemetrexed-induced cytotoxicity through and autophagy-dependent mechanism in cancer cells
… pathways known to regulate cell survival. Pemetrexed, an FDA-approved anti-folate drug, targets thymidylate synthase (TS) and a secondary folate-dependent enzyme, 5’ aminoimidazole-carboximide ribonucleotide formyltransferase (AICART); both important for DNA synthesis. Studies performed by …
-
Pemetrexed in primary central nervous system lymphoma: a phase-I dose finding study
… and tolerability of a novel anti-folate drug, pemetrexed, in the setting of a phase I clinical trial in patients with non-HIV related central nervous system lymphoma (CNSL). METHODS: In this multicenter, open-label, phase I dose finding clinical trial, pemetrexed was investigated as a single …
-
Pemetrexed-based chemotherapy for lung cancer treatment The delicate balance between efficacy and toxicity
Contains fulltext : 246882.pdf (Publisher’s version ) (Open Access)
-
Pemetrexed, A Modulator of AMP-activated Kinase Signaling and an Inhibitor of Wild type and Mutant p53
… mesothelioma, leukemia, and breast cancers. When pemetrexed (PTX) was discovered, our laboratory had established that the primary mechanism of action of pemetrexed is to inhibit thymidylate 22 synthase (TS) (E. Taylor et al., 1992). Preclinical studies have shown that PTX has a broad range of …
-
Discovery and Development of Predictive Biomarkers for the Personalization of Pemetrexed Therapy in Non-Small Cell Lung Cancer
… rates to the FDA-approved chemotherapeutic pemetrexed. To do so, clinically-applicable response phenotypes of a large panel of lung cancer lines needed to be defined to identify gene expression profiles driving response to pemetrexed treatment. To mimic clinical exposure and duration in …
-
ANTIFOLATE MODULATORS OF AMP-ACTIVATED PROTEIN KINASE SIGNALING AS CANCER THERAPEUTICS
… it was appreciated that the antifolate pemetrexed had multiple targets within folate metabolism. This laboratory was instrumental in showing that pemetrexed elicited its primary action as a thymidylate synthase inhibitor. Unusual for an antifolate, pemetrexed showed significant clinical …
-
RHEB DYNAMICS ON LYSOSOMAL MEMBRANES DETERMINES MTORC1 ACTIVITY AFTER LOSS OF P53 OR ACTIVATION OF AMPK
… PTEN, LKB1, and Akt. The antifolate pemetrexed was found by this laboratory to activate AMPK via the inhibition of the enzyme AICART in de novo purine synthesis. This work presents a mechanism of mTORC1 activation with p53 loss, as well as of mTORC1 inhibition by pemetrexed-induced …
-
Crystal Structures of Binary and Ternary Complexes of Thymidylate Synthase (ThyA) from Mycobacterium tuberculosis: Insights into Selectivity and Inhibition
… inhibitor, shown to have a Ki of 2nM for Mtb TS. Pemetrexed and Raltitrexed are both anti-folates, targeting the cofactor binding site of thymidylate synthase. The x-ray crystal structures of Mycobacterium tuberculosis thymidylate synthase were solved in the binary complexes ThyA-dUMP and …
-
Αναδρομική καταγραφή χημειοθεραπείας δεύτερης γραμμής σε ασθενείς με μεσοθηλίωμα
ΠΕΡΙΛΗΨΗ Ο συνδυασμός πλατίνας-pemetrexed αποτελεί τον χρυσό κανόνα στην χημειοθεραπεία πρώτης γραμμής ασθενών με μεσοθηλίωμα. Η συχνή όμως υποτροπή, κάνει την επιλογή χημειοθεραπείας δεύτερης γραμμής κρίσιμη για αυτούς. Στην πτυχιακή αυτή εργασία μελετήθηκαν αναδρομικά 98 ασθενείς με κακόηθες …
-
AN ECONOMIC ANALYSIS OF THE ADDITION OF BEVACIZUMAB TO STANDARD CHEMOTHERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA
… III trial, MAPS (Mesothelioma Avastin Cisplatin Pemetrexed Study), investigated the addition of bevacizumab to cisplatin plus pemetrexed (PCB) as compared to pemetrexed plus cisplatin (PC) alone in malignant pleural mesothelioma (MPM) patients. The trial results indicate that patients taking …
-
THERAPEUTIC EFFICACY OF COMBINATION OF MTOR INHIBITORS AND AMPK ACTIVATORS IN NON-SMALL CELL LUNG CANCER.
Pemetrexed (PTX), an antifolate drug, has been approved by the US FDA for first line therapy of mesothelioma and non-small cell lung cancer. In addition to its primary site of action on thymidylate synthase (TS), PTX also inhibits the second folate-dependent enzyme of purine biosynthesis …
-
Personalized Pharmacological Approaches as the Cornerstone of Modern Lung Cancer Therapy
… biomarkers for immunotherapy, and the use of pemetrexed in patients with impaired kidney function. Our research shows that interactions between SMIs and blood thinners (DOACs) often require dose adjustments or alternatives to prevent bleeding or thrombosis. Additionally, we found that the …
-
Synthesis and Characterization of Polymeric Nanoparticle Structures for Control Drug Delivery in Cancer Therapies and Temperature Effects on Drug Release
… characteristics. The encapsulation of the drug pemetrexed was improved by using polyethileneimine. The high positive charge density of polyethileneimine causes a strong electrostatic interaction with the carboxylic acids of pemetrexed; this complex decreases the solubility of pemetrexed and …
-
Opportunities in optimizing cytotoxic treatment of lung cancer in the era of immunotherapy
… and personalize the dosing of carboplatin, pemetrexed, docetaxel, and atezolizumab in the treatment of advanced non-small cell lung cancer (NSCLC) patients.. For carboplatin, it is recommended to adopt cystatin C-based estimation of drug clearance. This approach incorporates patient-specific …
-
Mechanism and Functional Consequence of MRP2 Mislocalization in Nonalcoholic Steatohepatitis
… of Mrp2 transport capacity was completed using pemetrexed, a novel Mrp2 probe substrate. Comparison of biliary excretion of pemetrexed between wild-type and Mrp2^(-/-) rats shows a 100% decrease, confirming that it relies upon Mrp2 for biliary excretion. NASH rats exhibited a 60% decrease in …
-
Προσδιορισμός του δείκτη κόστους αποτελεσματικότητας κατά τη διαχείριση ασθενών με καρκίνο του πνεύμονα στην Ελλάδα: ένα νέο θεωρητικό υπόδειγμα οικονομικής αξιολόγησης και οι πρακτικές του εφαρμογές για την δημόσια υγεία
… multicenter, randomized, trial, to evaluate pemetrexed relative to erlotinib in pre-treated patients with metastatic non small cell lung cancer (NSCLC) in Greece. Methods: We developed a new model which combines the cost-effectiveness and budget impact analysis in a unique model. The proposed …
Page 1 of 3